TX103 / Fuzhou Tcelltech Biotech - LARVOL DELTA

Tcelltech Secures USD 40 Million Series B Funding for TX-103 CAR-T Therapy Development (flcube.com) - "China-based Tcelltech...has reportedly secured close to USD 40 million in a Series B financing round. The funding was led by CS Capital, with participation from a prominent insurance fund and Lotus Lake Capital. Additional support came from institutions such as China Industrial International Trust Asset Management. The proceeds will be allocated to the clinical development of the company’s core pipeline product, TX-103, in both China and the U.S. The funds will also support the R&D of other pipeline projects, global team expansion, and the acceleration of the company’s international strategic layout and business development (BD) collaborations....TX-103, a B7-H3-targeted CAR-T cell therapy, has entered global regulatory clinical studies for solid tumors, including recurrent glioblastoma (rGBM)."

Financing • Glioblastoma

Effect of 4-1BBL-OX40L fusion protein on the anti-tumor activity of CAR-T cells in solid tumors. (ASCO 2025) - " Both 4-1BBL and the 4-1BBL-OX40L fusion protein significantly enhanced B7-H3 CAR-T cell proliferation and cytotoxicity... These results suggest that co-expressing 4-1BBL-OX40L fusion protein improves anti-tumor activity of B7-H3-targeted CAR-T cells against solid tumors in vitro and in vivo. B7-H3-targeted CAR-T cells co-expressing 4-1BBL-OX40L fusion protein is a promising treatment for solid tumors."

CAR T-Cell Therapy • IO biomarker • Brain Cancer • Colon Cancer • Colorectal Cancer • Glioblastoma • Hematological Malignancies • Oncology • Solid Tumor • CD4 • CD8 • HAVCR2 • IFNG • PD-1 • TIGIT • TNFSF4

Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma (clinicaltrials.gov) - P1 | N=30 | Active, not recruiting | Sponsor: Beijing Tiantan Hospital | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2024 ➔ Dec 2026

Enrollment closed • Trial completion date • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • CD276

Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma. (clinicaltrials.gov) - P1 | N=52 | Recruiting | Sponsor: Tcelltech Inc. | Not yet recruiting ➔ Recruiting | Initiation date: Jun 2024 ➔ Sep 2024

Enrollment open • Trial initiation date • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Malignant Glioma • Oncology • Solid Tumor • IFNG • IL10 • IL2 • IL6 • TNFA

A Phase I, Open-Label, Single/Multiple Dose, Dose-escalation Study to Evaluate the Safety, Tolerability and Antitumor Activity of TX103 CAR-T Cell Injection (TX103) in Subjects with Recurrent or Progressive Grade 4 Glioma. (ChiCTR) - P1 | N=39 | Not yet recruiting | Sponsor: Tiantan Hospital, Beijing, China; Fuzhou Tcelltech Biological Science and Technology Inc.

New P1 trial • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor • BRAF • CD276 • NTRK

Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma. (clinicaltrials.gov) - P1 | N=52 | Not yet recruiting | Sponsor: Tcelltech Inc.

CAR T-Cell Therapy • New P1 trial • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor • IFNG • IL10 • IL2 • IL6 • TNFA

Orphan Designation: Treatment of Malignant Glioma (FDA) - Date Designated: 06/21/2023

Orphan drug • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor